Daratumumab Shows Promise in Heavily Treatment-Resistant Multiple Myeloma - European Medical Journal

Daratumumab Shows Promise in Heavily Treatment-Resistant Multiple Myeloma

Oncology

A phase II trial suggests that anti-CD38 antibody daratumumab is effective as a standalone therapy for heavily treated multiple myeloma. In a group of 106 patients whose disease worsened after at least three prior treatments, nearly one in three responded to daratumumab, and disease progression was delayed by 3.7 months, on average. The estimated one-year overall survival rate was 65%.

Presented by Saad Zafar Usmani, MD, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC, at ASCO 2015.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>